Chromatography Columns are suited for UPLC and HPLC.
Press Release Summary:
Designed to work with ACQUITY® UltraPerformance LC® products, ACQUITY UPLC® OST C18 Columns are designed to purify and analyze synthetic oligonucleotides including siRNA, primers and probes, and therapeutic drugs. XBridge(TM) OST C18 columns are designed for advanced oligonculeotide HPLC separations. Featuring sub-3 micron Bridged Ethyl Hybrid (BEH) particle technology, both are suitable for ion-pair, reversed-phase separations of oligonucleotides.
Original Press Release:
New Column Offerings for UPLC and HPLC
Milford, Mass., February 21, 2007 - Waters Corporation (NYSE:WAT) announced today the introduction of two new sets of columns for the purification and analysis of oligonucleotides. The ACQUITY UPLC® OST C18 Columns are specifically designed to work with Waters family of ACQUITY® UltraPerformance LC® products. The XBridge(TM) OST C18 columns are designed for advanced oligonculeotide HPLC separations. Both products are ideal for purifying and analyzing synthetic oligonucleotides including siRNA, primers and probes, therapeutic drugs made by oligonucleotide manufacturers, diagnostic kit makers, government and university laboratories, and biotechnology companies.
The columns feature sub-3 micron Bridged Ethyl Hybrid (BEH) particle technology and yield significantly better resolution for ion-pair, reversed-phase separations of oligonucleotides than commercially-available columns for the same application. The 1.7 µm particle ACQUITY UPLC OST columns, besides offering improved resolution, offer scientists the speed and sample throughput they have come to expect from Waters UPLC technology.
In tests conducted at key accounts prior to launch, scientists were able to see up to a four-fold improvement in speed of analysis without any diminishment in resolution. In one case, a firm with a 60-minute reversed-phase HPLC assay featuring 48 injections (48 hours worth of work) for a 44mer oligonucleotide, reduced its total analysis time to 12 hours. Other accounts that tested the new columns realized similar productivity gains.
Lifetime expectancy of the new columns is greater than 1,000 injections.
Other recently introduced columns in the Waters BEH particle technology line include columns for peptide and amino acid analysis. The columns are now available from Waters worldwide.
Waters will be exhibiting both lines of OST C18 columns at Pittcon, February 25 - March 2, 2007 in booth # 3641 at McCormick Place, Chicago, IL. The company will be conducting a seminar titled Successful Separation of Synthetic Oligonucleotides in Less than 5 Minutes, Wednesday, February 28 at 11:30 a.m. in Seminar Room SR48.
Waters scientists presented a poster featuring applications for the new columns at EuroTIDES in November titled Developing Strategies for the Isolation and Purification of Synthetic Peptides.
For more information on either OST column line, scientists may visit waters.com/OST.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT) creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.
Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
With revenue of $1.28 billion in 2006 and 4,500 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.
Contact:
Brian J. Murphy
Corporate Communications
+1 508-482-2614
brian_j_murphy@waters.com
